GBI Research, the leading business intelligence provider, has released its latest research “Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market”, which essentially provides insights into antivirals therapeutics sales forecasts until 2017. The report covers the key geographies of the US, the top five countries in the European region and Japan. Insights into the antiviral research and development pipeline and the potential future blockbusters by 2017 are included. The report provides an in-depth analysis of HIV, hepatitis, herpes and influenza therapeutic indications, and includes market forecasts and treatment usage patterns for these four therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving antiviral therapies is also presented.